Lexaria Bioscience (Lexaria Bioscience) EV-to-EBIT : 0.00 (As of Jun. 18, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lexaria Bioscience's Enterprise Value is $0.00 Mil. Lexaria Bioscience's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-5.25 Mil. Therefore, Lexaria Bioscience's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Lexaria Bioscience's EV-to-EBIT or its related term are showing as below:

During the past 13 years, the highest EV-to-EBIT of Lexaria Bioscience was 31.23. The lowest was -60.89. And the median was -4.35.

LEXXW's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.37
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lexaria Bioscience's Enterprise Value for the quarter that ended in Feb. 2024 was $0.00 Mil. Lexaria Bioscience's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-5.25 Mil. Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was %.

Lexaria Bioscience EV-to-EBIT Historical Data

The historical data trend for Lexaria Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience EV-to-EBIT Chart

Lexaria Bioscience Annual Data

Trend

Oct13

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EV-to-EBIT

Get a 7-Day Free Trial

-13.08

-7.22

-4.18

-1.69

-1.04

Lexaria Bioscience Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															-2.29	-0.39	-1.04	-2.23	-7.19

Competitive Comparison of Lexaria Bioscience's EV-to-EBIT

For the Biotechnology subindustry, Lexaria Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's EV-to-EBIT falls into.

Lexaria Bioscience EV-to-EBIT Calculation

Lexaria Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-5.247
	=	0.00

Lexaria Bioscience's current Enterprise Value is $0.00 Mil.
Lexaria Bioscience's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.25 Mil.

Lexaria Bioscience (NAS:LEXXW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lexaria Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 )	=	EBIT	/	Enterprise Value (Q: Feb. 2024 )
	=	-5.247	/	0
	=	%

Lexaria Bioscience's Enterprise Value for the quarter that ended in Feb. 2024 was $0.00 Mil.
Lexaria Bioscience's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.25 Mil.

Lexaria Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

LEXX:USA

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.